## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 1.4% below STRENGTH zone (4.0-10.0%); PEG 3.69 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($98.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 9, Bearish: 0)

**1. Medtronic launches insulin delivery system with Abbott-made sensor**
- Source: MedTech Dive | 20251203T222733 | Bullish | Relevance: 100%
- Medtronic has launched its MiniMed 780G insulin pump integrated with Abbott's new Instinct glucose sensor, marking the first time Medtronic has partnered with an external company for a sensor. The Instinct sensor offers a 15-day wear time, which is longer than Medtronic's current CGMs. This rollout follows an expanded FDA label for the MiniMed 780G system, allowing it to be paired with third-party continuous glucose monitors.

**2. Medtronic gets FDA nod for Hugo surgical robot in urologic procedures**
- Source: MassDevice | 20251203T215935 | Bullish | Relevance: 100%
- Medtronic's Hugo robotic-assisted surgery system has received FDA clearance for urologic procedures in the U.S., marking its first U.S. approval for a soft-tissue surgical robot. The modular platform, which is already used internationally, aims to provide U.S. surgeons with a versatile tool to expand robotic surgery programs. Medtronic plans to pursue indications for general and gynecologic surgical procedures in the future.

**3. Medtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures**
- Source: Medtronic | 20251203T213254 | Bullish | Relevance: 100%
- Medtronic announced that its Hugo™ robotic-assisted surgery (RAS) system has received FDA clearance for urologic surgical procedures in the U.S. This clearance introduces a new choice for hospitals and surgeons looking to expand their robotic surgery programs and enhance patient access to minimally invasive care. The Hugo RAS system features a modular design, an integrated digital ecosystem with the Touch Surgery™ platform, and a differentiated partnership approach, supporting urologic procedures like prostatectomy, nephrectomy, and cystectomy.

**4. Medtronic (NYSE: MDT) gains FDA clearance for Hugo RAS in 230,000-case urology market**
- Source: Stock Titan | 20251203T213000 | Bullish | Relevance: 100%
- Medtronic (NYSE: MDT) has received FDA clearance for its Hugo™ robotic-assisted surgery (RAS) system for minimally invasive urologic procedures such as prostatectomy, nephrectomy, and cystectomy. These procedures account for approximately 230,000 surgeries annually in the U.S. The clearance follows a successful Expand URO IDE study, with Medtronic planning a purposeful U.S. launch and aiming for broader specialty indications in the future.

**5. Medtronic names Jeb Denny as chief medical officer for acute care and monitoring**
- Source: MedTech Dive | 20251203T050000 | Somewhat-Bullish | Relevance: 100%
- Medtronic has appointed Jeb Denny as the chief medical officer for its acute care and monitoring business, effective Tuesday. Denny joins Medtronic from BD and will lead the unit formed last year by combining Medtronic's patient monitoring and respiratory businesses, which generated $1.9 billion in sales in fiscal year 2025. He is board-certified in nephrology and internal medicine and will continue to practice medicine part-time.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Valuation stretched: PEG 3.7x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 3.69 signals overvaluation risk, limited margin of safety. Forward P/E 16.7x stretched relative to 8% growth. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $123.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.69 |
| Forward P/E | 16.7 |
| Current P/E | 18.0 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 8.5% to 1.4% (-7.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >4.0% for momentum thesis). MRS_5 (-2.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 3.4% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -STL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.42% (CS: 67) | Neutral |
| RSI_14 | 61.4 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.034x | Above |
| vs SMA50 | 1.059x | Above |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.97
- **Stop Loss:** $98.03 (3.9% risk)
- **Target:** $105.91 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 241
- **Position Value:** $24,574.77
- **Portfolio %:** 24.57%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*